ICREC Research Group offers a predoctoral position of 4 years (FPI program related to research project SAF2014-59892; PI Dr. Antoni Bayés-Genís).

Vacant no longer available.

PhD student in Cardiac Regeneration

ICREC Research Group

The research group for “Heart Failure and Cardiac Regeneration” (ICREC),  located at Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Institut del Cor and headed by Prof. Antoni Bayés-Genís, is inviting applications for PhD student in the field of Cardiac Regeneration.

ICREC Research Group offers a predoctoral position of 4 years  (FPI program related to research project  SAF2014-59892; PI Dr. Antoni Bayés-Genís).

 Eligibility criteria:

  • Comply with the requirements described in the website MINECO (Ayudas for predoctoral Contratos for Training of doctors in 2015) and to fill in the on line application as described the call*.
  • Enthusiastic researchers with a Degree in biomedical sciences and interest in cardiovascular research (Biology, Biochemistry, Biotechnology, Medicine or Veterinary Science).
  • Have finished a Master Degree before December 2015.
  • Good spoken and written command of English
  • Previous lab experience will be positively evaluated
  • Training in animal experimentation accreditation will be also valued (Category C)


  •  Curriculum vitae
  • Academic records
  • Recommendation letter



The deadline for submission of applications to the MINECO web ends on June 29

* See requirements and fill  in the application online



The research group on Insuficiència cardíaca i Regeneració cardiaca (ICREC), located at the Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Institut del Cor (www.icor.cat), chaired by Dr. Antoni Bayes-Genis, is a consolidated research laboratory with accreditation by Generalitat de Catalunya since 2009.

ICREC research group investigation is focussed in two main areas, one more clinical and another basic-translational. From the clinical stand-point, the group is interested in developing novel biomakers for diagnosis and prognosis in heart failure and sudden death as well as telemedicine. At the basic-translational level the group is interested in cell therapy and cardiac tissue engineering to salvage and restore injured myocardium.

The group is composed by investigators, with great experience in heart failure patient management, cell culture and processing histopathological samples, molecular biology, immunohistochemistry, and confocal microscopy techniques. We have also personal with extensive experience in the murine and porcine models both performing infarcts by coronary ligation after thoracotomy or by angiography.

The research project in which the candidate will join is entitled Value of induced pluripotent stem (iPS) cells-derived cardiomyocytes in cardiac physiopathology and regeneration (SAF2014-59892).

Tissue engineering procedures have emerged as advanced options to increase the regeneration of whole organs or locally damaged tissues. These strategies are based on the combination of cells with regenerative capacity, biological matrices, biocompatible synthetic polymers and/or online registration systems. In recent years our group has developed several prototypes of myocardial bioprosthesis for cardiac repair, including biological and synthetic materials refilled with different sources of mesenchymal progenitor cells, mainly of adipose origin (SAF2008-05144-C02-01; SAF2011-30067-C02-01; 7FP: NMP3-SL-2009-229239). The results in both murine and porcine models have been promising, yet cardiac contractility and tissue restoration remained insufficient, and new cardiac grafts need to be tested with novel materials and more committed cardiac precursors. Development of human cardiomyocytes derived from iPS cells opens new opportunities for in vitro models of cardiac disease, screening for new drugs, and patient-specific cardiac therapy. iPS-derived cardiomyocytes may be proper cell candidates since they represent an indefinite self-renewing supply of consistent starting material and a highly reproducible cellular model to study the basis and treatments of human diseases (i.e. inherited hypertrophic cardiomyopathy -HCM-). Moreover, the present project is a step forward in our aim to develop successful tissue engineered cardiac grafts. Here we propose to create novel bioactive implants by combining iPS-derived cardiomyocytes from human or porcine origin with biocompatible scaffolds, both in the murine and the swine models of myocardial infarction.

For more information and to send documentation: 

Grup ICREC, Institut del Cor, Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol

Ctra. de Can Ruti, camí de les escoles, s/n. 08916 – Badalona

Tel.: 93 497 86 62

grupicrec@gmail.com; abayesgenis@gmail.com